GlassScriptPhysician profile
Ervin Garcia
NPI 1649094988
$6,030.93
in general payments reported to CMS, 2019-2025
31 companies · $5,822 in 2025
The $5,822 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $209 · 2025: $5,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,030.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,118.18 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Axsome Therapeutics, INC. | $544.72 | 2025 | Symbravo, Auvelity |
| Abbvie INC. | $527.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $347.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $334.31 | 2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $305.97 | 2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $260.62 | 2025 | Gemtesa |
| Amgen INC. | $257.82 | 2025 | Evenity, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.26 | 2025 | Caplyta |
| Cequr Corporation | $228.76 | 2025 | Cequr Simplicity |
| Exact Sciences Corporation | $220.30 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $209.63 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $170.94 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $155.29 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $133.10 | 2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $130.90 | 2025 | |
| Pfizer INC. | $120.49 | 2025 | |
| Novartis Pharmaceuticals Corporation | $114.89 | 2025 | |
| Glaxosmithkline, LLC. | $78.05 | 2025 | Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $68.02 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.52 | 2025 | Jardiance |
| Radius Health, INC. | $56.72 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $53.59 | 2025 | |
| Shield Therapeutics INC | $52.46 | 2025 | |
| Phathom Pharmaceuticals, INC. | $50.51 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $49.90 | 2025 | Heplisav-B |
| Edwards Lifesciences Corporation | $40.71 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.06 | 2025 | Trintellix |
| Neurocrine Biosciences, INC. | $22.86 | 2025 | |
| Organon LLC | $21.41 | 2025 | Nexplanon |
| Esperion Therapeutics, INC. | $18.21 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ervin Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.